Profile data is unavailable for this security.
About the company
Zai Lab Ltd is a holding company mainly engaged in the biopharmaceutical field. The Company is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The Company has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.
- Revenue in USD (TTM)291.07m
- Net income in USD-338.95m
- Incorporated2013
- Employees2.18k
- LocationZai Lab Ltd4560 Jinke Road, Bldg. 1, 4/F, PudongSHANGHAI 201210ChinaCHN
- Phone+86 2 161632588
- Fax+86 2 161632570
- Websitehttps://www.zailaboratory.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Arvinas Inc | 71.30m | -354.80m | 1.76bn | 445.00 | -- | 2.88 | -- | 24.64 | -6.05 | -6.05 | 1.22 | 8.93 | 0.0597 | -- | 12.08 | 160,224.70 | -29.59 | -22.01 | -37.90 | -26.47 | -- | -- | -495.65 | -316.55 | -- | -- | 0.0012 | -- | -40.26 | 40.53 | -30.02 | -- | 0.4852 | -- |
| Catalyst Pharmaceuticals Inc | 411.35m | 65.12m | 1.78bn | 167.00 | 27.97 | 3.17 | 17.64 | 4.32 | 0.5384 | 0.5384 | 3.60 | 4.76 | 0.7806 | 3.60 | 8.76 | 2,463,156.00 | 12.36 | 25.42 | 14.19 | 29.81 | 86.74 | 85.63 | 15.83 | 30.87 | 4.83 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Keros Therapeutics Inc | 234.00k | -160.30m | 1.78bn | 141.00 | -- | 3.92 | -- | 7,611.54 | -5.14 | -5.14 | 0.0075 | 12.59 | 0.0005 | -- | -- | 1,720.59 | -36.84 | -35.95 | -38.35 | -38.07 | -- | -- | -68,505.13 | -1,237.26 | -- | -- | 0.00 | -- | -- | -56.77 | -46.15 | -- | 62.57 | -- |
| Zai Lab Ltd - ADR | 291.07m | -338.95m | 1.89bn | 2.18k | -- | 2.39 | -- | 6.48 | -3.50 | -3.50 | 3.00 | 7.83 | 0.2697 | 2.84 | 5.61 | 133,825.80 | -31.41 | -37.72 | -36.81 | -42.72 | 62.86 | 64.75 | -116.45 | -282.44 | 4.43 | -- | 0.0596 | -- | 24.03 | 360.03 | 24.51 | -- | -3.45 | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 1.89bn | 570.00 | -- | 4.61 | -- | 6.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Immunocore Holdings PLC - ADR | 265.83m | -59.44m | 1.92bn | 497.00 | -- | 5.32 | -- | 7.24 | -1.20 | -1.20 | 5.27 | 7.23 | 0.3486 | 0.406 | 5.60 | 534,860.40 | -7.80 | -27.55 | -9.40 | -36.82 | 99.60 | -- | -22.36 | -97.12 | 5.94 | -- | 0.5489 | -- | 43.05 | 51.23 | -5.22 | -- | 2.85 | -- |
| Protagonist Therapeutics Inc | 314.95m | 162.11m | 1.96bn | 124.00 | 13.58 | 3.49 | 12.01 | 6.22 | 2.46 | 2.46 | 5.25 | 9.56 | 0.7248 | -- | 2.10 | 2,812,080.00 | 37.30 | -35.90 | 40.23 | -41.36 | -- | -- | 51.47 | -332.81 | -- | -- | 0.00 | -- | 125.73 | 14.17 | 38.02 | -- | 4.62 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 1.97bn | 55.00 | -- | 5.55 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Amphastar Pharmaceuticals Inc | 676.21m | 154.69m | 1.98bn | 1.76k | 13.95 | 2.94 | 9.85 | 2.93 | 2.90 | 2.90 | 12.70 | 13.77 | 0.576 | 2.79 | 5.66 | 383,991.50 | 13.33 | 9.42 | 15.75 | 11.56 | 54.73 | 47.83 | 23.14 | 15.23 | 1.72 | 8.48 | 0.4692 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Rocket Pharmaceuticals Inc | 0.00 | -249.31m | 1.98bn | 268.00 | -- | 4.49 | -- | -- | -2.87 | -2.87 | 0.00 | 4.87 | 0.00 | -- | -- | 0.00 | -49.16 | -35.26 | -52.49 | -37.49 | -- | -- | -- | -- | -- | -- | 0.0458 | -- | -- | -- | -10.70 | -- | 62.52 | -- |
| Novavax Inc | 996.61m | -398.71m | 2.02bn | 1.54k | -- | -- | -- | 2.03 | -3.18 | -3.18 | 8.46 | -6.18 | 0.6882 | 14.75 | 14.85 | 645,890.50 | -27.53 | -46.06 | -460.95 | -269.57 | 63.04 | -- | -40.01 | -75.94 | 0.8843 | -27.04 | -- | -- | -50.36 | 95.68 | 17.16 | -- | 108.28 | -- |
| Kymera Therapeutics Inc | 79.41m | -154.59m | 2.04bn | 186.00 | -- | 2.87 | -- | 25.72 | -2.50 | -2.50 | 1.29 | 11.59 | 0.1072 | -- | 29.69 | 424,668.40 | -20.86 | -23.03 | -22.67 | -27.64 | -- | -- | -194.67 | -207.82 | -- | -- | 0.0032 | -- | 67.84 | -- | 5.07 | -- | 91.01 | -- |
| Beam Therapeutics Inc | 360.91m | -134.74m | 2.05bn | 436.00 | -- | 2.24 | -- | 5.67 | -1.74 | -1.74 | 4.54 | 11.10 | 0.2681 | -- | -- | 827,777.50 | -10.01 | -24.54 | -11.79 | -29.26 | -- | -- | -37.33 | -211.96 | -- | -- | 0.00 | -- | 520.01 | -- | 54.16 | -- | 20.78 | -- |
| Vericel Corp | 207.78m | 451.00k | 2.06bn | 314.00 | 4,423.64 | 8.77 | 380.62 | 9.89 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
Data as of Jun 14 2024. Currency figures normalised to Zai Lab Ltd's reporting currency: US Dollar USD
28.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Wellington Management Co. LLPas of 23 May 2024 | 6.29m | 6.34% |
| Capital Research & Management Co. (World Investors)as of 31 Mar 2024 | 5.68m | 5.73% |
| Janus Henderson Investors US LLCas of 31 Mar 2024 | 4.42m | 4.46% |
| Woodline Partners LPas of 31 Mar 2024 | 2.60m | 2.62% |
| Viking Global Investors LPas of 31 Mar 2024 | 2.05m | 2.06% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 1.65m | 1.66% |
| BAMCO, Inc.as of 31 Mar 2024 | 1.60m | 1.61% |
| Segantii Capital Management Ltd.as of 31 Mar 2024 | 1.56m | 1.57% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 1.36m | 1.37% |
| Rock Springs Capital Management LPas of 31 Mar 2024 | 1.30m | 1.31% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
